Baiyee

Baiyee specializes in delivering fiscal and compliance solutions for pharmaceutical companies, enhancing the efficiency of marketing activities and ensuring adherence to regulatory standards nationwide in China. Baiyee 贝医科技 was founded in 2015 in Shanghai, China, focusing on compliance solutions in the pharmaceutical sector. The founder, Shenglin Cong, has a history in the industry, though details of prior ventures are not specified. The firm has completed 2 deals with their most recent deal on June 30, 2017, when they raised Series A funding from Jingbei Investment.

Baiyee 贝医科技 provides comprehensive fiscal and compliance solutions tailored for pharmaceutical companies. Their offerings include a digital platform with a risk control engine, compliance data, and standard templates, which streamline budgeting, project execution, and tax processes, thereby enhancing operational efficiency. They cater to a diverse clientele across state-owned enterprises, private firms, and publicly listed companies in China, ensuring compliance with regulatory standards during marketing activities. Baiyee 贝医科技 generates revenue through a combination of one-time consultation fees, ongoing service subscriptions, and comprehensive project-based agreements within a B2B model.

Their revenue structure includes fixed pricing for specific services alongside variable costs determined by the scope of consulting engagements. Their key revenue-generating product is the integrated compliance management system, which assists clients in optimizing marketing efficiency while managing compliance risks. Baiyee plans to leverage its recent Series A funding, raised in June 2017, to enhance its product offerings and expand into new markets. They are developing upcoming products aimed at improving compliance mechanisms within the pharmaceutical sector, with a focus on launching these innovations by the end of 2023.

Additionally, Baiyee intends to target expansion into regional markets beyond Shanghai, seeking opportunities in the Greater Bay Area and other major Chinese cities by 2025.